Bharat Book Bureau Provides the Trending Market Research Report on “Global Immune Checkpoint Inhibitors Biomarkers & Clinical Trials Insight 2028 "under Life Sciences Market Research Report Category. The report offers a collection of superior market research, market analysis, competitive intelligence and Market reports.
Global Immune Checkpoint Inhibitors Biomarkers and Clinical Trials Insight 2028 Report Highlights:
Global Immune Checkpoint Inhibitors Market Opportunity: > USD 30 Billion
Immune Checkpoint Inhibitors Clinical Trials Insight: CTLA-4, LAG3, PD-1/PD-L1, TIGIT Inhibitors
Immune Checkpoint Inhibitors Clinical Trials Insight: > 300 Drugs In Trials
Biomarkers Insight By Immune Checkpoint Inhibitors Classification
Insight On Biomarkers Sourced From Trials By Drugs and Indication
Biomarker Name and Function Insight By Immune Checkpoint Inhibitor Drug
Biomarker Insight Based On Drugs In Multiple Trials Phase and Multiple Indication
Cancer biomarker is a traceable substance or molecules which indicate the presence of cancerous cells. The prevention of cancer by diagnosing and analyzing various cancer biomarkers using different diagnostic techniques is a profound approach to obtain rapid results for treatment. There are various types of biomarkers such as proteins, peptides, antibodies, and nucleic acids. The presence of these biomarkers in tissues, urine, serum, blood, and other body fluids indicate an abnormal process or a disease.
Various such biomarkers for cancer indications have been studied and are used as biomarkers for diagnostics, prognostics, personalized medicines, and surrogate endpoints. The identification of different types of biomarkers is an integral part of various industries such as healthcare and pharmaceuticals.
Among all targeted approaches, immune checkpoint inhibitors have gained the maximum interest in the market. To date, several immune checkpoint inhibitors have entered the market and various others are present in clinical development, thus driving this sector during the forecast period. However, these immune checkpoint inhibitors are shown to be effective in about 20%-30% of the cancer patients. Therefore, there is unmet need to develop and validate accurate biomarkers to assist immune checkpoint therapy in cancer patients.
Currently, the FDA has approved three predictive biomarkers for immune checkpoint inhibitor therapy in cancer patients including programmed cell death ligand-1 (PD-L1); microsatellite instability (MSI), and tumor mutational burden (TMB). Apart from this, several others are present in clinical development. The report provides comprehensive analysis on the ongoing clinical trials related to biomarker for approved immune checkpoint inhibitors as well as inhibitors which are under clinical trials. Furthermore, the role of biomarker in different therapeutic conditions is also mentioned in the report.
Many pharmaceutical companies are actively investing in research and development of novel biomarkers for the diagnosis and treatment of cancer. Many potential candidates are in their end stage of development and are projected to give a tremendous boost to the market after their launch.
Recently in 2022, Personalis announced a strategic alliance with the Moores Cancer Center at University of California San Diego Health, a National Cancer Institute-designated Comprehensive Cancer Center, to support clinical diagnostic testing in patients with advanced solid tumors and hematological malignancies. The collaboration will bring Personalis’ leading comprehensive genomic tumor profiling test to UC San Diego health care professionals and their cancer patients to help guide FDA-approved therapy decisions, as well as clinical trial treatment options.
The US will continue to dominate the global market in terms of biomarker research and Immune checkpoint inhibitor sales during the forecast period driven by several factors including higher adoption of advanced technologies like next generation sequencing, and the increasing number of research studies establishing the role of biomarkers in drug discovery and development, and cancer diagnosis. Additionally, rising prevalence of cancer in the region and surge in awareness among population regarding the availability of biomarkers will also aid in the growth of market.
Furthermore, rapid approval of diagnostic tests in the region will also propel the growth of the market. For instance in 2022, Oxford BioDynamics announced the US launch of its checkpoint inhibitor test (EpiSwitch CIRT) for cancer.
The global immune checkpoint inhibitor biomarkers market is expected to witness a significant growth during the forecast period due to increase in prevalence of various types of cancers such as breast, prostate, and lung cancer. In addition, surge in importance of biological and targeted drug therapies, technological advancements, accuracy, and reliability of cancer biomarkers also contribute toward the growth of the market.
Moreover, increase in investments from governments and public and private sector toward research and development for cancer diagnostics have a positive impact on the market. The key players in the market include Roche, Abbott, Thermo Fisher Scientific, Centogene, Myriad, and others.
Browse our full report with Table of Content :
About Bharat Book Bureau:
Bharat Book is Your One-Stop-Shop with an exhaustive coverage of 7,80,000 reports and insights that includes latest Market Study, Market Trends & Analysis, Forecasts Customized Intelligence, Newsletters and Online Databases. Overall a comprehensive coverage of major industries with a further segmentation of 100+ subsectors.
Contact us at:
Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Email: [email protected]